Last week, San Francisco became the latest and largest city in America to decriminalize psychedelics, including psilocybin mushrooms and ayahuasca. This move to decriminalize comes as a Senate bill from the state of California, which called for the decriminalization of psilocybin mushrooms, DMT, MDMA, LSD and ibogaine, was put on ice until 2023.
During a meeting held last week, San Francisco’s Board of Supervisors unanimously approved a resolution that would make arresting individuals for the use, cultivation and distribution of federally banned psychedelics the lowest enforcement priority for law enforcement in the county. The resolution was introduced and sponsored by San Francisco Supervisors Dean Preston and Hillary Ronen. It states that psychedelics have demonstrated that they could be beneficial for individuals dealing with anxiety, trauma and addiction, highlighting that they could also benefit individual psychological and physical wellness.
The measure, which decriminalized plant-based psychedelics such as ayahuasca, psilocybin mushrooms and peyote, also stipulates that no city resources should be used in investigations, prosecutions or detentions involving the use of psychedelics. This is in addition to calling for the federal and state governments to decriminalize psychedelics. Further, it urges the mayor to instruct federal and state lobbyists to support efforts to decriminalize entheogenic plants and compounds under Schedule I.
Preston stated that through this move, San Francisco joins a growing list of cities and nations that are viewing these plant-based medicines through a new lens, following available data and science, and destigmatizing their cultivation and use.
The city’s decision to decriminalize psychedelics follows similar measures passed in other jurisdictions, including Washington, DC, Santa Cruz, Oakland and Denver. In 2019, Denver became the first city in America to decriminalize psychedelics, which encouraged legislators and activists around the country to follow suit.
In November 2020, Oregon was the first state in the country to fully legalize the use of hallucinogenic mushrooms in the treatment of a range of mental health conditions. It is expected that facilities where individuals can access psychedelic-assisted treatment will be launched next year.
Voters in the state approved Measure 109 in the ballot, which also decriminalized psilocybin. It should be noted that the sale, use and possession of psilocybin is still illegal under federal law. Other states in the country are also making strides to better understand psychedelics and the benefits they possess.
For instance, states such as Texas, Hawaii, Washington and Connecticut have established working groups to conduct research on the effectiveness of psychedelics as mental health treatments.
As advocates push for the decriminalization and even legalization of psychedelics, many for-profit entities such as Silo Pharma Inc. (OTCQB: SILO) are focused on taking their drug-development programs through the rigorous clinical-development process so that they can be approved by the FDA and other agencies overseeing healthcare systems around the world.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.